Wall Street brokerages expect that Adamis Pharmaceuticals Corp (NASDAQ:ADMP) will report earnings per share of ($0.08) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Adamis Pharmaceuticals’ earnings. The highest EPS estimate is ($0.05) and the lowest is ($0.11). Adamis Pharmaceuticals posted earnings per share of ($0.21) in the same quarter last year, which would indicate a positive year-over-year growth rate of 61.9%. The company is scheduled to report its next earnings report on Friday, November 8th.
On average, analysts expect that Adamis Pharmaceuticals will report full year earnings of ($0.46) per share for the current year, with EPS estimates ranging from ($0.53) to ($0.40). For the next financial year, analysts anticipate that the business will report earnings of ($0.17) per share, with EPS estimates ranging from ($0.26) to ($0.08). Zacks’ EPS averages are an average based on a survey of sell-side research firms that cover Adamis Pharmaceuticals.
Adamis Pharmaceuticals (NASDAQ:ADMP) last announced its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.03). The company had revenue of $5.77 million during the quarter, compared to the consensus estimate of $5.82 million. Adamis Pharmaceuticals had a negative return on equity of 86.04% and a negative net margin of 205.32%.
Several brokerages have recently issued reports on ADMP. Maxim Group set a $6.00 price target on Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 9th. ValuEngine cut Adamis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, September 4th. Dawson James began coverage on Adamis Pharmaceuticals in a research report on Tuesday, July 2nd. They set a “buy” rating on the stock. Zacks Investment Research cut Adamis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 13th. Finally, B. Riley upgraded Adamis Pharmaceuticals from a “sell” rating to a “neutral” rating in a research report on Tuesday, July 23rd. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Adamis Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $3.87.
ADMP remained flat at $$0.74 during trading hours on Friday. The company had a trading volume of 535,279 shares, compared to its average volume of 876,453. Adamis Pharmaceuticals has a 12-month low of $0.70 and a 12-month high of $4.25. The company has a quick ratio of 0.79, a current ratio of 1.04 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $45.46 million, a price-to-earnings ratio of -0.74 and a beta of 1.33. The business’s fifty day moving average is $0.93 and its 200-day moving average is $1.56.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. DekaBank Deutsche Girozentrale acquired a new stake in shares of Adamis Pharmaceuticals in the first quarter worth about $3,360,000. Morgan Stanley lifted its position in shares of Adamis Pharmaceuticals by 189.7% in the second quarter. Morgan Stanley now owns 757,124 shares of the specialty pharmaceutical company’s stock worth $984,000 after buying an additional 495,793 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Adamis Pharmaceuticals in the second quarter worth about $181,000. Vanguard Group Inc. increased its stake in shares of Adamis Pharmaceuticals by 4.5% in the second quarter. Vanguard Group Inc. now owns 1,791,266 shares of the specialty pharmaceutical company’s stock worth $2,328,000 after purchasing an additional 77,498 shares during the period. Finally, A.R.T. Advisors LLC increased its stake in shares of Adamis Pharmaceuticals by 143.8% in the second quarter. A.R.T. Advisors LLC now owns 61,711 shares of the specialty pharmaceutical company’s stock worth $80,000 after purchasing an additional 36,400 shares during the period. 12.09% of the stock is owned by hedge funds and other institutional investors.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
Featured Article: 12b-1 Fees
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.